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incidence of cardiac adverse events were followed up at the time of 1
and 6 months.
RESULTS The designed number were 1140 patients, now it was the
results of 188 patients(the control group was 87 and experimental
group was 101). The basic clinical characteristics and complicated
disease were not signiﬁcantly different(P>0.05). The creatinine,
creatinine clearance rate and glomerular ﬁltration rate were not
signiﬁcantly different in control group before and after the oper-
ation(P¼0.823, P¼0.87 and P¼0.93). The same results were gained in
experimental group(P¼0.153, P¼0.16 and P¼0.21). There were no
difference of changing degree of creatinine, creatinine clearance rate
and glomerular ﬁltration rate before and after the PCI between the
control and experimental group (P¼0.398, P¼0.065 and P¼0.956). The
incidence of CIN in control group was 8.05%, and the incidence of CIN
in experimental group was only 2.97%, but there was no difference
also (P¼0.12).
CONCLUSIONS The primary results shows that the left ventricular
end-diastolic pressure and brain natriuretic peptide guided low-dose
furosemide may be beneﬁcial for preventing contrast-induced ne-
phropathy in the percutaneous coronary intervention, but the
conclusion need further observations to prove.
International Clinical Trials Register main ID: ChiCTR-IOR-14005250.
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Relationship between clopidogrel metabolism polymorphism and variable
platelet reactivity in 1 year: a cohort study
Wang Xiaodong, Yan Lai, Yu Luo, Jiani Tang, Zi Ye, Xuebo Liu
Department of Cardiology, Shanghai East Hospital, Tongji University
School of Medicine, Shanghai, China
OBJECTIVES To investigate the effect of clopidogrel polymorphism
on platelet reactivity and clinical outcome.
METHODS 236 PCI-treated patients were recruited and followed up
for one year in a cardiovascular monocenter. All blood samples of
patients were collected, and deoxyribonucleic acid (DNA) were gen-
otyped. Platelet reactivity unit (PRU) was measured by VerifyNow
technique as well. CYP2C19, ABCB1, ITGB3, PON1 and P2RY12 allele
were assessed.
RESULTS 236 patients were genotyped and ﬁnished one year follow
up. Clinical endpoints were related to previous heart disease history
(P ¼0.0172), stroke (P ¼0.0483) and diabetes (P ¼0.0474). High
treatment on platelet reactivity (HTPR) were frequent in old age
(P ¼0.0187), male gender (P ¼0.0159), hypertension (P ¼0.0334), heart
disease history (P ¼0.0484) and chronic renal failure (CRF)
(P ¼0.0398). More mutant alleles were found in CYP2C19*2,
CYP2C19*17 and P2RY12 polymorphism (P <0.0001, P ¼0.0025 and
P ¼0.0021, respectively). Patients carrying these three alleles man-
ifested HTPR (P ¼0.00021, 0.00255 and 0.00848, respectively).
However, there was no more cardiovascular deaths in endpoint pa-
tient (for CYP2C19*2 P ¼0.886, for CYP2C19*17 and P2Y12 P ¼1.0).
CONCLUSIONS Clopidogrel-related gene polymorphism are related to
decreasing platelet reactivity after clopidogrel maintaining dose,
increasing major adverse cardiovascular events, without effect on
cardiovascular death.
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Lipoprotein-associated phospholipase A2 and Multi-vessel Disease Predict
the Progression of Nonculprit Lesions in Patients with Acute Coronary
Syndrome After Percutaneous Coronary Intervention
Rui Zhang, Haichu Yu
Department of Cardiology, Afﬁliated Hospital of Qingdao University
OBJECTIVES To elucidate the association of Lipoprotein-associated
phospholipase A2 (Lp-PLA2) activity with progression of nonculprit
lesions undergoing percutaneous coronary intervention (PCI) in pa-
tients with Acute Coronary Syndrome (ACS).
METHODS Our study was comprised 468 Chinese patients with ACS
who treated with PCI from January 2008 to January 2011 in Afﬁliated
Hospital of Qingdao University. All patients were divided into two
groups according to the progression of nonculprit lesions after PCI.
The progressive group was consisted of 152 patients while the
nonprogressive group was consisted of 316 patients. All patients
completed a questionnaire on present condition, family and medical
histories of cardiovascular risk factors and complications, and the
results of coronary angiography. Furthermore, fasting blood samplewas collected from each patient before and after PCI 24 hours to
determine Lp-PLA2 activity.
RESULTS ① The proportion of multi-vessel disease was signiﬁcantly
higher inprogressive group than those in nonprogressive group (P<0.05).
②Compared with nonprogressive group, the mean level of Lp-PLA2 ac-
tivity of progressive group before and after PCI 24 hours were signiﬁ-
cantly higher, and the level of Lp-PLA2 activity after PCI was higher than
before in all patients (12.376.27 nmol/min/ml vs 8.923.16nmol/min/
ml), (21.435.28 nmol/min/ml vs 14.864.18 nmol/min/ml, P<0.05).
CONCLUSIONS Lp-PLA2 activity and multi-vessel disease may predict
the progression of nonculprit lesions after PCI.
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Impacts of Anticoagulation with Bivalirudin versus Low Molecular Weight
Heparin on Thrombopenia during IABP Therapy
Yuan Wang, Hua Xiao, Jinxia Zhang, Zhihua Gong, Dingcheng Xiang
Guangzhou military general hospital
OBJECTIVES Comparing the impacts of low molecular weight heparin
and bivalirudin on blood platelet counts as well as the level of anti-
body of platelet factor 4 heparin-dependent antibodies (H-PF4 IgG)
during IABP therapy.
METHODS This pilot study was designed to totally enroll 60 patients
of AMI complicated cardiac shock who underwent PPCI and IABP
procedure (during or after PPCI). Enoxaparin or bivalirudin were
respectively used as anticoagulation drugs in the heparin group and
the bivalirudin group during IABP therapy after PPCI. Intravenous
blood samples were collected at different time, including before IABP
procedure, at 2 hours, every 24 hours after IABP implantation and
until 72 hours after IABP withdrawn, to measure platelets related
indices, red blood cell related indices, hemolysis related indices and
antibody of H-PF4 IgG. Bone marrow smear to discover the prolifer-
ation status if patients signed informed consent to undergo bone
marrow puncture after IABP withdrawn.
RESULTS The average IABP courses were not signiﬁcantly different be-
tween the heparin group and the bivalirudin group [(4.451.50) day versus
(4.401.47) day, P ¼0.891]. Thrombopenia was developed in 13 patients in
the research, and the incidence of thrombocytopenia was 25%. The general
tendency of platelet changes in the two groups showed that the count went
down rapidly after implantation of IABP and then went slightly up slowly
until the withdrawn of IABP. Once withdrawing IABP, platelet count rose
rapidly and even surpassed the baseline level. The decrease of platelet
number was remarkably smaller in bivalirudin group than in heparin group
(P¼0.043),but therewerenosigniﬁcantdifferencesbetweenthetwogroups
whencomparingat the same timepoints ( P>0.05).Thenumberof redblood
cells, hemoglobinquantitativeandhemotocrit of amplitudeofchangeswere
greater in the heparin group than in bivalirudin group (P < 0.05), and the
basic level of total bilirubin andunconjugated bilirubinweremuchhigher in
the heparin group than in the bivalirudin group (P <0.05). Before implan-
tationof IABP, therewasno signiﬁcantdifferencebetweenthe twogroups in
the level of antibody to H-PF4 IgG (P>0.05). However, the level of antibody
toH-PF4 IgGwasmuchhigher in theheparingroup than inbivalirudingroup
(P¼0.043). and the increase amplitude of antibody toH-PF4 IgGwas greater
in the heparin group than in the bivalirudin group (P ¼0.048).
CONCLUSIONS 1. Platelets number went down rapidly after implan-
tation of IABP and got to the lowest level at the 3rd day, then regained
slowly and got back or even surpassed to the baseline after the
withdrawn of IABP.
2. Mechanical rupture of platelets was the major mechanism of
thrombopenia during IABP therapy when heparin-induced-thrombo-
penia also played an very important role in it.
3. Compared with low molecular weight heparin, bivalirudin
showed a potential to reduce the incidence of thrombopenia while
used as a anticoagulation during IABP therapy.
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Impact of different time periods on symptom onset- ﬁrst medical contact
and door-to-balloon time in patients with acute ST-segment elevation
myocardial infarction
Peilin Liu, Li Liu, Jingtao Zhao, Hongyong Song, Bei Zhao,
Xueyao Feng, Lifeng Liu, Yingqi Liu, Shuai Mao, Li Zhou, Huihui Xia,
Tieshan Gao, Shouli Wang
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China
OBJECTIVES The law of onset time was very important to prognostic
of patients with acute myocardial infarction. This study investigated
